IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer
PURPOSETo describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population.PATIENTS AND METHODSInitiated in 2017, IRONMAN (International Registry for Men with Advanced Prost...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2022-11-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.22.00154 |
| _version_ | 1811330602724491264 |
|---|---|
| author | Lorelei A. Mucci Jacob Vinson Theresa Gold Travis Gerke Julie Filipenko Rebecca M. Green Simon G. Anderson Simone Badal Anders Bjartell Kim N. Chi Ian D. Davis Deborah Enting André P. Fay John Lazarus Joaquin Mateo Ray McDermott Folakemi T. Odedina David Olmos Aurelius Omlin Ademola A. Popoola Camille Ragin Robin Roberts Kjell M. Russnes Charles Waihenya Konrad H. Stopsack Terry Hyslop Paul Villanti Philip W. Kantoff Daniel J. George |
| author_facet | Lorelei A. Mucci Jacob Vinson Theresa Gold Travis Gerke Julie Filipenko Rebecca M. Green Simon G. Anderson Simone Badal Anders Bjartell Kim N. Chi Ian D. Davis Deborah Enting André P. Fay John Lazarus Joaquin Mateo Ray McDermott Folakemi T. Odedina David Olmos Aurelius Omlin Ademola A. Popoola Camille Ragin Robin Roberts Kjell M. Russnes Charles Waihenya Konrad H. Stopsack Terry Hyslop Paul Villanti Philip W. Kantoff Daniel J. George |
| author_sort | Lorelei A. Mucci |
| collection | DOAJ |
| description | PURPOSETo describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population.PATIENTS AND METHODSInitiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires.RESULTSThrough July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service.CONCLUSIONTo our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer. |
| first_indexed | 2024-04-13T16:04:49Z |
| format | Article |
| id | doaj.art-c2ac1375880a4f8296dca71b57375939 |
| institution | Directory Open Access Journal |
| issn | 2687-8941 |
| language | English |
| last_indexed | 2024-04-13T16:04:49Z |
| publishDate | 2022-11-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj.art-c2ac1375880a4f8296dca71b573759392022-12-22T02:40:25ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412022-11-01810.1200/GO.22.00154IRONMAN: A Novel International Registry of Men With Advanced Prostate CancerLorelei A. Mucci0Jacob Vinson1Theresa Gold2Travis Gerke3Julie Filipenko4Rebecca M. Green5Simon G. Anderson6Simone Badal7Anders Bjartell8Kim N. Chi9Ian D. Davis10Deborah Enting11André P. Fay12John Lazarus13Joaquin Mateo14Ray McDermott15Folakemi T. Odedina16David Olmos17Aurelius Omlin18Ademola A. Popoola19Camille Ragin20Robin Roberts21Kjell M. Russnes22Charles Waihenya23Konrad H. Stopsack24Terry Hyslop25Paul Villanti26Philip W. Kantoff27Daniel J. George28Harvard T.H. Chan School of Public Health, Boston, MAProstate Cancer Clinical Trials Consortium, New York, NYProstate Cancer Clinical Trials Consortium, New York, NYProstate Cancer Clinical Trials Consortium, New York, NYProstate Cancer Clinical Trials Consortium, New York, NYProstate Cancer Clinical Trials Consortium, New York, NYThe Glasgow-Caribbean Centre for Development Research and the Caribbean Institute of Health Research, The University of the West Indies, Bridgetown, BarbadosThe University of the West Indies Mona, Kingston, JamaicaSkåne University Hospital, Malmö, SwedenBC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, CanadaMonash University, Melbourne, AustraliaGuys St Thomas NHS Foundation Trust, London, United KingdomHospital Sao Lucas da PUCRS, Porto Alegre, BrazilUniversity of Cape Town, Cape Town, South AfricaVall d’Hebron Institute of Oncology, Barcelona, SpainSt Vincent's University Hospital & Cancer Trials Ireland, Dublin, IrelandMayo Clinic, Jacksonville, FLHospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, SpainKantonsspital St Gallen, St Gallen, SwitzerlandUniversity of Ilorin, Ilorin, NigeriaFox Chase Cancer Center, Philadelphia, PAUWI School of Clinical Medicine and Research, Nassau, The BahamasOslo University Hospital, Oslo, NorwayUniversity of Nairobi, Nairobi, KenyaHarvard T.H. Chan School of Public Health, Boston, MADuke Cancer Institute, Durham, NCMovember Foundation, Melbourne, AustraliaConvergent Therapeutics, Cambridge, MADuke Cancer Institute, Durham, NCPURPOSETo describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population.PATIENTS AND METHODSInitiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires.RESULTSThrough July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service.CONCLUSIONTo our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.https://ascopubs.org/doi/10.1200/GO.22.00154 |
| spellingShingle | Lorelei A. Mucci Jacob Vinson Theresa Gold Travis Gerke Julie Filipenko Rebecca M. Green Simon G. Anderson Simone Badal Anders Bjartell Kim N. Chi Ian D. Davis Deborah Enting André P. Fay John Lazarus Joaquin Mateo Ray McDermott Folakemi T. Odedina David Olmos Aurelius Omlin Ademola A. Popoola Camille Ragin Robin Roberts Kjell M. Russnes Charles Waihenya Konrad H. Stopsack Terry Hyslop Paul Villanti Philip W. Kantoff Daniel J. George IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer JCO Global Oncology |
| title | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer |
| title_full | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer |
| title_fullStr | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer |
| title_full_unstemmed | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer |
| title_short | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer |
| title_sort | ironman a novel international registry of men with advanced prostate cancer |
| url | https://ascopubs.org/doi/10.1200/GO.22.00154 |
| work_keys_str_mv | AT loreleiamucci ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT jacobvinson ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT theresagold ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT travisgerke ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT juliefilipenko ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT rebeccamgreen ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT simonganderson ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT simonebadal ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT andersbjartell ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT kimnchi ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT ianddavis ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT deborahenting ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT andrepfay ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT johnlazarus ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT joaquinmateo ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT raymcdermott ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT folakemitodedina ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT davidolmos ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT aureliusomlin ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT ademolaapopoola ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT camilleragin ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT robinroberts ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT kjellmrussnes ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT charleswaihenya ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT konradhstopsack ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT terryhyslop ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT paulvillanti ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT philipwkantoff ironmananovelinternationalregistryofmenwithadvancedprostatecancer AT danieljgeorge ironmananovelinternationalregistryofmenwithadvancedprostatecancer |